公开(公告)号：US10428076B2

公开(公告)日：2019-10-01

申请号：US16019964

申请日：2018-06-27

申请人： Merck Sharp & Dohme Corp.

发明人： Raphaelle Berger ,  Yi-Heng Chen ,  Guoqing Li ,  Joie Garfunkle ,  Hong-Dong Li ,  Shouwu Miao ,  Subharekha Raghavan ,  Cameron J. Smith ,  John Stelmach ,  Alan Whitehead ,  Rui Zhang ,  Yong Zhang ,  Jianmin Fu ,  Gang Ji ,  Falong Jiang

IPC分类号： C07D487/04 ,  C07D519/00 ,  A61K31/519 ,  A61K45/06

摘要： The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

公开(公告)号：US20180305366A1

公开(公告)日：2018-10-25

申请号：US16019964

申请日：2018-06-27

申请人： Merck Sharp & Dohme Corp.

发明人： Raphaelle Berger ,  Yi-Heng Chen ,  Guoqing Li ,  Joie Garfunkle ,  Hong-Dong Li ,  Shouwu Miao ,  Subharekha Raghavan ,  Cameron J. Smith ,  John Stelmach ,  Alan Whitehead ,  Rui Zhang ,  Yong Zhang ,  Jianmin Fu ,  Gang Ji ,  Falong Jiang

IPC分类号： C07D487/04 ,  A61K31/519 ,  C07D519/00 ,  A61K45/06

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  C07D519/00

摘要： The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

公开(公告)号：US10030027B2

公开(公告)日：2018-07-24

申请号：US15384429

申请日：2016-12-20

申请人： MERCK SHARP & DOHME CORP.

发明人： Raphaelle Berger ,  Yi-Heng Chen ,  Guoqing Li ,  Joie Garfunkle ,  Hong-Dong Li ,  Shouwu Miao ,  Subharekha Raghavan ,  Cameron J. Smith ,  John Stelmach ,  Alan Whitehead ,  Rui Zhang ,  Yong Zhang ,  Jianmin Fu ,  Gang Ji ,  Falong Jiang

IPC分类号： C07D487/04 ,  C07D519/00 ,  A61K45/06 ,  A61K31/519

摘要： The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.